Kodiak Sciences Inc. (KOD)
Kodiak Sciences Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in Palo Alto, CA, US. The stock last traded at $32.35, down 2.62% on the session, giving a market capitalisation of $2.02B. On trailing twelve-month figures it carries a trailing P/E of -7.72, a net margin of 0.0%. Its beta of 2.18 implies it has historically moved more than the broad market.
Kodiak Sciences Inc. is a biopharmaceutical firm currently in the clinical development phase, dedicated to discovering, advancing, and bringing to market treatments for various conditions affecting the retina. Their primary drug candidate, KSI-301, is an anti-vascular endothelial growth factor (anti-VEGF) antibody biopolymer. This compound is currently undergoing Phase IIb/III clinical trials, targeting illnesses such as wet age-related macular degeneration (AMD), diabetic macular edema, previously untreated macular edema resulting from retinal vein occlusion, and non-proliferative diabetic retinopathy. In its earlier, preclinical development pipeline, the company is also working on KSI-501, a bispecific conjugate designed for retinal conditions involving inflammation, and KSI-601, a triplet inhibitor aimed at addressing dry AMD. Established in 2009, this Palo Alto, California-based company operated under the name Oligasis, LLC before rebranding as Kodiak Sciences Inc. in September 2015.
Kodiak Sciences Inc. is most often compared with the following Healthcare names: